CSF1R and neoplasm: In agreement with previous reports, the addition of anti-CSF-1R to anti-PD-L1 + anti-TIGIT partially depleted macrophages from the tumour beds of treated mice (Extended Data Fig. 9a) and sustained tumour responsiveness to checkpoint inhibitors (Extended Data Fig. 9b).